Deng et al. (2017) showed that low CHAD expression was significantly associated with poor survival in hepatocellular carcinoma. In our analysis, CHAD was significantly downregulated in HNSCC samples, and its low expression was associated with a high-risk score and poor prognosis in both patients with LSCC and OSCC (Figure 4). This evidence concerns the gene CHAD and hepatocellular carcinoma.